Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial.

Precis Clin Med · 2026 · PMC12856360 · PMID 41625230

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Notably, patients with low MUC3A expression showed a trend toward greater benefit from T-DXd, suggesting that the expression level of MUC3A may serve as an additional criterion to optimize treatment selection.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.